Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Description of key information

Not expected to be carcinogenic under occupational exposure conditions.

Key value for chemical safety assessment

Carcinogenicity: via oral route

Endpoint conclusion
Endpoint conclusion:
no study available

Carcinogenicity: via inhalation route

Endpoint conclusion
Endpoint conclusion:
no study available

Carcinogenicity: via dermal route

Endpoint conclusion
Endpoint conclusion:
no study available

Justification for classification or non-classification

No alerts for carcinogenicity were obtained using DEREK, Lhasa, Leeds, UK.

Additional information

·     Only a limited number of glucocorticoids have been tested for carcinogenicity, but some have produced an increase in hepatocullular tumours when tested via the oral route. This is thought to be due to exaggerated pharmacological activity at high doses that are probably not relevant to occupational exposure.  

·     A single study reports an increase incidence of rare bone tumours in Sprague Dawley rats following two years dietary dosing at 0.25 mg/kg/day with Deflazacort, but this was not seen in a parallel study in mice. 

·     Available studies for fluticasone propionate and fluticasone furoate, two potent steroids, conducted via the inhalation route were negative. 

No alerts for carcinogenicity were obtained using DEREK, Lhasa, Leeds, UK.